Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer | NEJM
Innovazione e nuove prospettive di cura nel Carcinoma della Mammella
Final Analysis of SOLAR-1: 8-Month Survival Benefit Misses Statistical Significance for Alpelisib - The ASCO Post
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients | Blood Cancer Journal
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer - Annals of Oncology
Aleix Prat #PrecisionOncology on Twitter: "@OncoAlert #ESMO20 @FAndreMD presents the Overall Survival Results From SOLAR-1, a Phase 3 Study of Alpelisib + Fulvestrant for HR+/HER2-neg Advanced Breast Cancer OS improved but not
The Solar Spectrum Challenge
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 - ScienceDirect
Metastasiertes Mammakarzinom: CDK4-6-Inhibitoren plus Fulvestrant überzeugen – Rosenfluh.ch
Aleix Prat #PrecisionOncology on Twitter: "@OncoAlert #ESMO20 @FAndreMD presents the Overall Survival Results From SOLAR-1, a Phase 3 Study of Alpelisib + Fulvestrant for HR+/HER2-neg Advanced Breast Cancer OS improved but not
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Cancer Trial Results
Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer | NEJM
Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer — Video Pr
Verlängertes Gesamtüberleben mit PI3K- und CDK4:6-Hemmer bei Hochrisikopatientinnen – Rosenfluh.ch
SOLAR-1 Study Design | PIQRAY® (alpelisib) tablets | HCP
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded ...
Overall and progression-free survival curves for uveal melanoma... | Download Scientific Diagram
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review - Poddubnaya - Journal of Modern Oncology
![ESMO 2020: [VIRTUAL] Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast](https://larvolclin.s3.us-west-2.amazonaws.com/resize_16281548762097847804610babfc2e18a.png "ESMO 2020: [VIRTUAL] Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast")
ESMO 2020: [VIRTUAL] Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast
SOLAR-1 Study Design | PIQRAY® (alpelisib) tablets | HCP
Recommendation No. 132/2021 of 3 December 2021 of the President of the Agency for Health Technology Assessment and Tariff System
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 - Annals of Oncology
Cancer Trial Results
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Final overall survival results of SOLAR-1 add to growing body of evidence for alpelisib - BJMO
